These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 25608599)

  • 1. The utility of 18 F-FDG PET/CT for suspected recurrent breast cancer: impact and prognostic stratification.
    Cochet A; David S; Moodie K; Drummond E; Dutu G; MacManus M; Chua B; Hicks RJ
    Cancer Imaging; 2014 Apr; 14(1):13. PubMed ID: 25608599
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical utility of F-18 FDG PET/CT in recurrent breast carcinoma.
    Manohar K; Mittal BR; Senthil R; Kashyap R; Bhattacharya A; Singh G
    Nucl Med Commun; 2012 Jun; 33(6):591-6. PubMed ID: 22334135
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Diagnostic and prognostic value of 18F-FDG PET/CT in recurrent germinal tumor carcinoma.
    Alongi P; Evangelista L; Caobelli F; Spallino M; Gianolli L; Midiri M; Picchio M
    Eur J Nucl Med Mol Imaging; 2018 Jan; 45(1):85-94. PubMed ID: 28828589
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 18F-FDG PET/CT is a prognostic biomarker in patients affected by bone metastases from breast cancer in comparison with 18F-NaF PET/CT.
    Piccardo A; Puntoni M; Morbelli S; Massollo M; Bongioanni F; Paparo F; Altrinetti V; Gonella R; Gennari A; Iacozzi M; Sambuceti G; DeCensi A
    Nuklearmedizin; 2015; 54(4):163-72. PubMed ID: 26165806
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recurrent bladder carcinoma: clinical and prognostic role of 18 F-FDG PET/CT.
    Alongi P; Caobelli F; Gentile R; Stefano A; Russo G; Albano D; Baldari S; Gilardi MC; Midiri M
    Eur J Nucl Med Mol Imaging; 2017 Feb; 44(2):224-233. PubMed ID: 27565154
    [TBL] [Abstract][Full Text] [Related]  

  • 6. FDG Avidity and Tumor Burden: Survival Outcomes for Patients With Recurrent Breast Cancer.
    Taghipour M; Wray R; Sheikhbahaei S; Wright JL; Subramaniam RM
    AJR Am J Roentgenol; 2016 Apr; 206(4):846-55. PubMed ID: 27003053
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Diagnostic and prognostic value of 18F-FDG PET/CT for patients with suspected recurrence from squamous cell carcinoma of the esophagus.
    Guo H; Zhu H; Xi Y; Zhang B; Li L; Huang Y; Zhang J; Fu Z; Yang G; Yuan S; Yu J
    J Nucl Med; 2007 Aug; 48(8):1251-8. PubMed ID: 17631554
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Negative 18F-2-fluorodeoxyglucose PET/CT predicts good cancer specific survival in patients with a suspicion of recurrent ovarian cancer.
    Hebel CB; Behrendt FF; Heinzel A; Krohn T; Mottaghy FM; Bauerschlag DO; Verburg FA
    Eur J Radiol; 2014 Mar; 83(3):463-7. PubMed ID: 24368010
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recurrent renal cell carcinoma: clinical and prognostic value of FDG PET/CT.
    Alongi P; Picchio M; Zattoni F; Spallino M; Gianolli L; Saladini G; Evangelista L
    Eur J Nucl Med Mol Imaging; 2016 Mar; 43(3):464-73. PubMed ID: 26268680
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of 2-[18F] fluoro-2-deoxy-D-glucose-positron emission tomography/computed tomography in the post-therapy surveillance of breast cancer.
    Chang HT; Hu C; Chiu YL; Peng NJ; Liu RS
    PLoS One; 2014; 9(12):e115127. PubMed ID: 25517451
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Risk stratification in patients with advanced-stage breast cancer by pretreatment [(18) F]FDG PET/CT.
    Chen S; Ibrahim NK; Yan Y; Wong ST; Wang H; Wong FC
    Cancer; 2015 Nov; 121(22):3965-74. PubMed ID: 26249241
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In newly diagnosed diffuse large B-cell lymphoma, determination of bone marrow involvement with 18F-FDG PET/CT provides better diagnostic performance and prognostic stratification than does biopsy.
    Berthet L; Cochet A; Kanoun S; Berriolo-Riedinger A; Humbert O; Toubeau M; Dygai-Cochet I; Legouge C; Casasnovas O; Brunotte F
    J Nucl Med; 2013 Aug; 54(8):1244-50. PubMed ID: 23674577
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The utility of (18)F-FDG PET for suspected recurrent non-small cell lung cancer after potentially curative therapy: impact on management and prognostic stratification.
    Hicks RJ; Kalff V; MacManus MP; Ware RE; McKenzie AF; Matthews JP; Ball DL
    J Nucl Med; 2001 Nov; 42(11):1605-13. PubMed ID: 11696628
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical and Prognostic Value of
    Albano D; Familiari D; Fornito MC; Scalisi S; Laudicella R; Galia M; Grassedonio E; Ruggeri A; Ganduscio G; Messina M; Spada M; Midiri M; Alongi P
    Curr Radiopharm; 2020; 13(1):42-47. PubMed ID: 31595860
    [TBL] [Abstract][Full Text] [Related]  

  • 15. ¹⁸F-FDG PET/CT provides powerful prognostic stratification in the primary staging of large breast cancer when compared with conventional explorations.
    Cochet A; Dygai-Cochet I; Riedinger JM; Humbert O; Berriolo-Riedinger A; Toubeau M; Guiu S; Coutant C; Coudert B; Fumoleau P; Brunotte F
    Eur J Nucl Med Mol Imaging; 2014 Mar; 41(3):428-37. PubMed ID: 24196916
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of ¹⁸F-FDG PET/CT for detecting recurrence of medullary thyroid carcinoma.
    Ozkan E; Soydal C; Kucuk ON; Ibis E; Erbay G
    Nucl Med Commun; 2011 Dec; 32(12):1162-8. PubMed ID: 21946617
    [TBL] [Abstract][Full Text] [Related]  

  • 17. FDG-PET/CT in the diagnosis of recurrent breast cancer.
    Murakami R; Kumita S; Yoshida T; Ishihara K; Kiriyama T; Hakozaki K; Yanagihara K; Iida S; Tsuchiya S
    Acta Radiol; 2012 Feb; 53(1):12-6. PubMed ID: 22067206
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Can (18)F-FDG PET/CT scan change treatment planning and be prognostic in recurrent colorectal carcinoma? A prospective and follow-up study.
    Artiko V; Odalovic S; Sobic-Saranovic D; Petrovic M; Stojiljkovic M; Petrovic N; Kozarevic N; Grozdic-Milojevic I; Obradovic V
    Hell J Nucl Med; 2015; 18(1):35-41. PubMed ID: 25840571
    [TBL] [Abstract][Full Text] [Related]  

  • 19. (18)F-fluorodeoxyglucose positron-emission tomography-computed tomography to diagnose recurrent cancer.
    You JJ; Cline KJ; Gu CS; Pritchard KI; Dayes IS; Gulenchyn KY; Inculet RI; Dhesy-Thind SK; Freeman MA; Chan AM; Julian JA; Levine MN
    Br J Cancer; 2015 May; 112(11):1737-43. PubMed ID: 25942398
    [TBL] [Abstract][Full Text] [Related]  

  • 20. ¹⁸F-FDG-PET/CT in staging, restaging, and treatment response assessment of male breast cancer.
    Groheux D; Hindié E; Marty M; Espié M; Rubello D; Vercellino L; Bousquet G; Ohnona J; Toubert ME; Merlet P; Misset JL
    Eur J Radiol; 2014 Oct; 83(10):1925-33. PubMed ID: 24985086
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.